N ext-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios ...

Prime Medicine (NASDAQ:PRME) and Bristol Myers Squibb (NYSE:BMY) will work together on the development of next-generation ex ...

Prime Medicine, Inc. (PRME – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Bristol Myers Squibb is paying Prime Medicine $110 million upfront to develop reagents for ex vivo T-cell therapies. Prime, ...

On Monday, Prime Medicine Inc (PRME) stock saw a modest uptick, ending the day at $3.87 which represents a slight increase of $0.41 or 11.85% from the prior close of $3.46. The stock opened at $4.23 ...

Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 ...

Prime Medicine, founded with gene-editing tech from the lab of star Harvard biochemist David Liu and backed by blue chip investors, made little secret of its ambition. It laid out plans to use ...

BMO Capital analyst Kostas Biliouris has reiterated their bullish stance on PRME stock, giving a Buy rating yesterday. Kostas Biliouris has ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in ...

Next-generation healthcare company Prime Medicine (NASDAQ: PRME) was exactly what the doctor ordered for ailing portfolios on the first trading day of the week. On a company update and news of ...

Arguably the more significant of the two pieces of news was that partnership deal. Prime Medicine announced that it had signed a strategic research collaboration and license agreement with global ...